Health Care [ 5/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.
The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors.
It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor.
BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 10, 25 | 1.08 Decreased by -43.16% | 0.37 Increased by +188.85% |
| Nov 4, 24 | 0.88 Increased by +31.34% | -1.70 Increased by +151.76% |
| Aug 5, 24 | -3.36 Decreased by -325.32% | -2.02 Decreased by -66.34% |
| May 6, 24 | -1.41 Decreased by -168.78% | -1.17 Decreased by -20.51% |
| Mar 20, 24 | 1.90 Decreased by -79.48% | 2.42 Decreased by -21.49% |
| Nov 6, 23 | 0.67 Decreased by -90.40% | -0.10 Increased by +770.00% |
| Aug 7, 23 | -0.79 Decreased by -112.25% | -0.96 Increased by +17.71% |
| May 8, 23 | 2.05 Decreased by -85.60% | 0.14 Increased by +1.36 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 1.19 B Decreased by -19.54% | 259.50 M Decreased by -43.33% | Increased by +21.81% Decreased by -29.57% |
| Sep 30, 24 | 1.23 B Decreased by -16.96% | 195.46 M Decreased by -57.31% | Increased by +15.91% Decreased by -48.60% |
| Jun 30, 24 | 129.35 M Decreased by -85.55% | -811.89 M Decreased by -605.53% | Decreased by -627.66% Decreased by -3.60 K% |
| Mar 31, 24 | 188.70 M Decreased by -85.22% | -316.95 M Decreased by -163.11% | Decreased by -167.96% Decreased by -527.10% |
| Dec 31, 23 | 1.48 B Decreased by -65.43% | 457.90 M Decreased by -79.91% | Increased by +30.96% Decreased by -41.87% |
| Sep 30, 23 | 1.48 B Decreased by -57.27% | 457.90 M Decreased by -74.35% | Increased by +30.96% Decreased by -39.96% |
| Jun 30, 23 | 895.30 M Decreased by -71.99% | 160.60 M Decreased by -90.39% | Increased by +17.94% Decreased by -65.71% |
| Mar 31, 23 | 1.28 B Decreased by -79.97% | 502.20 M Decreased by -86.42% | Increased by +39.33% Decreased by -32.22% |